drugset / Trial / NCT00708435

Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy

NCT00708435

Phase 3 Completed 216 enrolled CSL Behring
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR (International Normalized Ratio)and to stop an acute major bleeding.

Timeline

Start
2008-06
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Beriplex® P/N Protein / enzyme biologic Intravenous
Comparator Fresh Frozen Plasma Protein / enzyme biologic Intravenous